

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

**ADAPTIVE BIOTECHNOLOGIES CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Washington**  
(State or other jurisdiction of incorporation or organization)

**27-0907024**  
(I.R.S. Employer Identification No.)

**1551 Eastlake Avenue East, Suite 200**  
**Seattle, Washington**  
(Address of principal executive offices)

**98102**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

**Title of each class  
to be so registered**  
**Common Stock, \$0.0001 par value**

**Name of each exchange on which  
each class is to be registered**  
**The Nasdaq Stock Market LLC**

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

**Securities Act registration statement file number to which this form relates:**  
**333-231838**

**Securities to be registered pursuant to Section 12(g) of the Act:**  
**None.**

---

---

---

**Item 1. Description of Registrant's Securities to be Registered.**

A description of the common stock, par value \$0.0001 per share (the "Common Stock"), of Adaptive Biotechnologies Corporation, a Washington corporation (the "Registrant"), to be registered hereunder is contained in the section entitled "Description of Capital Stock" in the prospectus that constitutes a part of the Registrant's Registration Statement on Form S-1 (File No. 333-231838), as initially filed with the Securities and Exchange Commission (the "Commission") on May 30, 2019, and as subsequently amended (the "Registration Statement"), which information is hereby incorporated by reference. In addition, any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated by reference herein.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Date: June 26, 2019

Adaptive Biotechnologies Corporation

By: /s/ Chad Robins

Name: Chad Robins

Title: Chief Executive Officer